Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/DAD.0000000000002761 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rash and Intractable Pruritus After Hemodialysis Initiation: Challenge.
Am J Dermatopathol
October 2024
Department of Dermatology, Brigham and Women's Hospital, Boston, MA.
A 29-year-old female presented to a rheumatology-dermatology clinic with a pruritic rash that began 6 months prior, after a viral illness. She had previously been diagnosed with eczema and treated with antihistamines and topical steroids without improvement. She also noted fatigue, hair loss, and severe scalp pruritus.
View Article and Find Full Text PDFhand infection: a case report and literature review.
Front Med (Lausanne)
August 2024
Department of Clinical Laboratory, Hebei Medical University Third Hospital, Shijiazhuang, China.
, a photochromogenic, slow-growing mycobacterium, thrives in both marine and freshwater environments. Optimal growth occurs between 25°C and 35°C, with survival becoming challenging above 37°C. Typically, enters the body via skin abrasions, often leading to infections of the upper extremities.
View Article and Find Full Text PDFJapanese Public Health Insurance System's new genomic strategic action to shorten the "diagnostic odyssey" for patients with rare and intractable diseases.
J Hum Genet
November 2024
Center for Medical Genetics, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
In June 2024, the Japanese government introduced a new genomic strategic action to shorten the "diagnostic odyssey" for patients with rare and intractable diseases: Six groups of rare diseases, (i) Muscle weakness group, (ii) Growth retardation, intellectual disability, and characteristic facial features group, (iii) Intellectual disability/epilepsy group, (iv) Cardiomyopathy group (mainly adult onset) (v) Proteinuria group, (vi) Fever, inflammation, skin rash, osteoarthritis group, have been newly recognized as "difficult-to-differentiate disorders" and comprehensive genomic testing can be reimbursed when patients belong to one of the six groups and certain requirements are met. The introduction of comprehensive genomic testing will improve the diagnosis rate of diseases and have significant potential to enhance Japan's rare and intractable disease policy. The new strategy in Japan and its rationale will be a reference for insurance reimbursement of comprehensive genomic testing in other countries that have universal health coverage supported by the public health insurance system.
View Article and Find Full Text PDF[Efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Zhonghua Yi Xue Za Zhi
August 2024
Department of Dermatology, Xiangya Hospital, Central South University Hunan Key Laboratory of Skin Cancer and Psoriasis National Clinical Research Center for Geriatric Disorders, Changsha 410008, China.
To analyse the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis (AD). The clinical data of moderate to severe AD patients who received dupilumab therapy in the Department of Dermatology, Xiangya Hospital, Central South University from August 2020 to November 2022 were retrospectively analyzed. The efficacy was evaluated by Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI) before treatment and 2, 4, 16 and 24 weeks after treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!